Patent · US Active

VEGF specific fusion protein antagonist formulations

US9636400B2 · kind B2 · utility

43Cited by

15References

27Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Daniel Dix · Lagrangeville, US
Kelly Frye · Mendham, US
Susan KAUTZ · Albany, US

Key dates

Filing date	May 10, 2016
Grant date	May 2, 2017
Priority date	—
Expiry date	May 10, 2036

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.